What are Rho kinase inhibitor drugs?

Rho kinase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting ROCK1/ROCK2, norepinephrine transporter). 3 are currently marketed, with 3 more in clinical development.

What are the marketed Rho kinase inhibitor drugs?

Marketed Rho kinase inhibitor drugs include Netarsudil Ophthalmic, Rhopressa, Rocklatan 0.02%-0.005% Ophthalmic Solution.

Rho kinase inhibitor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 marketed 2 in Phase 3 1 in Phase 2

This page covers all Rho kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting ROCK1/ROCK2, norepinephrine transporter, rho kinase, Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK).

Targets

ROCK1/ROCK2, norepinephrine transporter · rho kinase · Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK) · Rho kinase (ROCK) · ROCK (Rho-associated coiled-coil containing protein kinase) · Rho kinase

Marketed (3)

Netarsudil Ophthalmic · University of the Incarnate Word · Ophthalmology
Netarsudil is a Rho kinase inhibitor and norepinephrine transporter antagonist that reduces intraocular pressure by increasing conventional outflow and decreasing episcleral venous pressure.
Rhopressa · Alcon Labs Inc · Cardiovascular
Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork.
Rocklatan 0.02%-0.005% Ophthalmic Solution · Eye Centers of Southeast Texas · Ophthalmology
Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production.

Phase 3 pipeline (2)

VEN 307 · Ventrus Biosciences, Inc · Ophthalmology
VEN 307 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow.
DE-114 ophthalmic solution · Santen Pharmaceutical Co., Ltd. · Ophthalmology
DE-114 is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.

Phase 2 pipeline (1)

Losmapimod tablets · GlaxoSmithKline · Cardiovascular
Rho kinase inhibitor

Patent intelligence

rho kinase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates